Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study.
Felix Carl Fabian SchmittVasil ManolovJakob MorgensternThomas FlemingStefan HeitmeierFlorian UhleMohammed Al-SaeediThilo HackertThomas BrucknerHerbert SchöchlMarkus Alexander WeigandStefan HoferThorsten BrennerPublished in: Annals of intensive care (2019)
Early inhibition of plasminogen activation leads to acute fibrinolysis shutdown with improved clot stability and is associated with increased morbidity and mortality in septic patients. Trial registration This study was approved by the local ethics committee (Ethics Committee of the Medical Faculty of Heidelberg; Trial-Code No. S247-2014/German Clinical Trials Register (DRKS)-ID: DRKS00008090; retrospectively registered: 07.05.2015). All study patients or their legal representatives signed written informed consent.
Keyphrases
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- liver failure
- public health
- septic shock
- healthcare
- phase ii
- randomized controlled trial
- respiratory failure
- phase iii
- acute kidney injury
- machine learning
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- open label